MDMA-assisted therapy for social anxiety disorder: A randomized, open-label, wait-list controlled trial.

Could MDMA-assisted therapy reduce social anxiety by not only alleviating symptoms but also improving psychological functioning and addressing underlying processes such as shame, self-compassion, acceptance and belonging?

This randomised, open-label, wait-list controlled trial investigated MDMA-assisted therapy in 20 adults with moderate-to-severe social anxiety disorder. The treatment involved preparatory psychotherapy, two MDMA-assisted sessions and subsequent integration sessions. At 16 weeks, participants receiving MDMA-assisted therapy showed a substantial reduction in social anxiety symptoms compared with the wait-list group, with a large between-group effect size (Hedges' g = 2.8), alongside improvements in psychological functioning. The study also explored changes in psychological processes including shame, acceptance, belonging, self-concealment and self-compassion. No serious adverse events were reported. The authors concluded that the findings provide preliminary evidence supporting further investigation of MDMA-assisted therapy for social anxiety disorder, while recognising the need for larger controlled studies to establish its efficacy and safety.

Abstract

Background

±3, 4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating Social Anxiety Disorder (SAD) in a previous placebo-controlled trial.

Aims

Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy manual and assessment of candidate therapeutic processes.

Method

This randomized, open-label, wait-list controlled clinical trial recruited and enrolled 20 participants diagnosed with SAD from April 2022 to March 2024. They were randomly assigned to either immediate treatment with MDMA-AT or a 16-week waitlist condition followed by MDMA-AT equivalent to the immediate treatment arm. MDMA-AT consisted of three 90-min preparation sessions, two MDMA sessions, and six 90-min integration sessions. The preregistered primary outcome was the Liebowitz Social Anxiety Scale; secondary outcomes were functioning, shame, acceptance, belongingness, self-concealment, and self-compassion.

Results

Across 20 participants (45% women, 40% men, 15% transgender; 85% White; mean age 38) we observed a mean difference on the Liebowitz Social Anxiety Scale at 16-week primary outcome of −43.3 (SD = 14.7; 95% CI, −29.5 to −57.1; p < .0001; Hedges’ g = 2.8) indicating greater improvement in the MDMA-AT condition. No serious adverse events occurred; adverse events were mild to moderate and transient.

Conclusions

MDMA-AT resulted in a significant reduction in social anxiety symptoms and improvement in functioning compared to waitlist. There were no serious adverse events. Findings provide preliminary data for clinical response, safety, and feasibility of MDMA-AT for SAD, supporting the need for further investigation.

Luoma, J.B., Lear, M.K., Pilecki, B., LeJeune, J., Yi, K., Chwyl, C., Mehr, S., Sarparast, A., Kennedy, L., Lucas, W., Spata, A. and Stauffer, C.S. (2026). MDMA-assisted therapy for social anxiety disorder: A randomized, open-label, wait-list controlled trial. Journal of Affective Disorders, 418, 122710. Read Paper

e psychedelic health professional network homepage.

Previous
Previous

Changes in wellbeing, self-compassion and alexithymia in a proof of principle trial with MDMA-assisted therapy for major depressive disorder

Next
Next

Acute Effects of Brief Mindfulness Inductions on Executive Function Performance: A Systematic Review and Three-Level Meta-Analysis